悦康药业(688658) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥577,383,322.42, representing a decrease of 40.35% compared to ¥967,900,022.68 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥49,271,134.83, a decline of 171.09% from a profit of ¥69,305,423.83 in the previous year[4] - The net cash flow from operating activities decreased by 44.54%, amounting to ¥81,041,633.19 compared to ¥146,130,897.27 in the prior year[4] - Total operating revenue for Q1 2025 was ¥577.38 million, a decrease of 40.4% compared to ¥967.90 million in Q1 2024[17] - Net profit for Q1 2025 was a loss of ¥49.50 million, compared to a profit of ¥69.12 million in Q1 2024, indicating a significant decline[18] - Operating profit for Q1 2025 was a loss of ¥58.45 million, contrasting with a profit of ¥80.36 million in Q1 2024[17] - Cash flow from operating activities for Q1 2025 was ¥81.04 million, down 44.5% from ¥146.13 million in Q1 2024[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,611,332,242.14, a decrease of 2.21% from ¥5,738,112,424.72 at the end of the previous year[5] - The company's current assets totaled RMB 3,037,807,721.74, down from RMB 3,157,931,976.13, indicating a decrease of about 3.8%[12] - Cash and cash equivalents increased to RMB 1,454,983,942.63 from RMB 1,331,795,660.80, representing a growth of approximately 9.2%[12] - Inventory decreased significantly from RMB 757,335,702.72 to RMB 645,468,495.43, a reduction of around 14.7%[12] - Total liabilities decreased from RMB 2,153,155,749.09 to RMB 2,075,873,810.65, a decline of about 3.6%[14] - The company's equity attributable to shareholders decreased from RMB 3,577,629,966.77 to RMB 3,528,358,831.94, a decrease of approximately 1.4%[14] - The company reported a short-term loan of RMB 103,133,365.43, down from RMB 112,965,265.65, reflecting a decrease of about 8.0%[14] - The company's accounts receivable stood at RMB 575,284,268.66, a slight decrease from RMB 611,698,533.96, indicating a reduction of approximately 6.0%[12] - The company's total non-current assets were RMB 2,573,524,520.40, slightly down from RMB 2,580,180,448.59, reflecting a decrease of about 0.3%[13] Research and Development - Research and development expenses totaled ¥99,271,226.53, which is an increase of 2.27% year-over-year, and accounted for 17.19% of total revenue, up by 10.03 percentage points[5] - The company is actively promoting and increasing investment in key R&D projects, including small nucleic acid drugs and peptide drugs, to maintain industry leadership[7] - Research and development expenses for Q1 2025 were ¥97.17 million, an increase of 13.6% from ¥85.50 million in Q1 2024[17] Sales and Marketing - The company plans to optimize sales strategies and maintain core sales channels to address the decline in revenue and profit[7] - Sales expenses for Q1 2025 were ¥130.66 million, down 55.6% from ¥294.03 million in Q1 2024[17] Financial Metrics - The weighted average return on equity was -1.39%, down by 3.31 percentage points from 1.92% in the previous year[4] - The basic and diluted earnings per share were both -¥0.11, a decrease of 173.33% from ¥0.15 in the same period last year[4] - The company incurred a financial expense of ¥3.61 million in Q1 2025, compared to a financial income of ¥0.54 million in Q1 2024[17]